Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Pharmaron Beijing Co., Ltd. Class H (3759) Stock Price & Analysis

11 Followers

3759 Stock Chart & Stats

HK$30.06HK$0.66(3.16%)
At close: 4:00 PM GMT+8
HK$27.5HK$30HK$32.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 29.70 - HKD 31.00
52-Week Range
HKD 14.45 - HKD 34.86
Previous Close
HKD 29.14
Volume
N/A
Average Volume (3M)
6.25M
Market Cap
HKD 87.98B
Enterprise Value
HKD 63.14B
Total Cash (Recent Filing)
HKD 4.03B
Total Debt (Recent Filing)
HKD 7.46B
Price to Earnings (P/E)
45.6
Beta
1.47
Next Earnings
Mar 29, 2027 (Est.)
EPS Estimate
0.51
Last Dividend Ex-Date
Jul 07, 2026
Dividend Yield
0.76%

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Robust multi-year and TTM revenue growth indicates continued demand for Pharmaron’s research, development, and manufacturing services. Sustained expansion can broaden customer relationships, improve operating scale, and support reinvestment across its integrated life-sciences platform over the next several quarters.

Integrated CRDMO Platform

An integrated CRDMO offering gives customers access to services across the drug-development lifecycle, potentially deepening relationships and increasing opportunities to capture work as programs advance. Coverage of both small molecules and biologics also supports a broad, diversified service proposition.

Reasonable Leverage And Positive Profitability

A debt-to-equity ratio of about 0.43 and a sizable equity base provide a reasonable financial foundation, while an approximately 11% TTM net margin confirms the business remains profitable. This combination supports ongoing operations and gives the company some capacity to fund its platform.

Bears Say

Margin Compression

The decline in net margin from roughly 22% to 11% shows that revenue growth has not translated into stable profitability at prior levels. Persistent compression would reduce earnings conversion, limit internal funding capacity, and make future growth less valuable if costs continue rising faster than revenue.

Negative Free Cash Flow

Negative TTM free cash flow despite positive operating cash flow indicates that investment or working-capital demands are absorbing reported earnings. If this persists, the company may have less internally generated cash for expansion, debt reduction, and shareholder returns, weakening overall earnings quality.

Rising Debt Burden

Although current leverage remains reasonable, the latest increase in total debt reduces financial flexibility and raises the importance of maintaining profitability and cash generation. Further debt growth alongside margin pressure could constrain capital allocation and increase sensitivity to weaker operating performance.

Pharmaron Beijing Co., Ltd. Class H News

3759 FAQ

What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$34.86 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$87.98B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s next earnings report is estimated for Mar 29, 2027 (not yet confirmed), which is in 138 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Oct 27, 2026. The company reported HK$0.319 earnings per share for the quarter, missing the consensus estimate of HK$0.345 by -HK$0.026.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays an annual dividend of HK$0.23 which represents an annual dividend yield of 0.76%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.51.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.319 in its last earnings report, missing expectations of HK$0.345. Following the earnings report the stock price went down -1.701%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology